HAIFA

Tactile Mobility Appoints Boaz Shpigelman as VP of Research & Development

Retrieved on: 
Monday, May 6, 2024
Research, Organization, Security printing

HAIFA, Israel, May 06, 2024 (GLOBE NEWSWIRE) -- Tactile Mobility, a technology company specializing in tactile sensing and data analytics for the automotive industry, announced the appointment of Boaz Shpigelman as vice president of research & development.

Key Points: 
  • HAIFA, Israel, May 06, 2024 (GLOBE NEWSWIRE) -- Tactile Mobility, a technology company specializing in tactile sensing and data analytics for the automotive industry, announced the appointment of Boaz Shpigelman as vice president of research & development.
  • Prior to joining Tactile Mobility, Boaz served as the vice president of research & development at Check-Cap, where he made significant contributions to the development of medical technologies.
  • Now, Boaz will spearhead Tactile Mobility's research and development initiatives, leveraging his experience to drive innovation and further advance the company's tactile sensing technology.
  • "We are pleased to welcome Boaz Shpigelman as our new VP of R&D," said Shahar Bin-Nun, CEO of Tactile Mobility.

Cellipont Bioservices and Adva Biotechnology Collaborate to Optimize Cell Therapy Manufacturing with the ADVA X3® Platform

Retrieved on: 
Tuesday, May 7, 2024
Learning, Quality control, Exosome, MD, Partnership, Cell, CDMO, TIL, Biotechnology, Patient, Gene, Society, Health, TCR, Annual general meeting, NK, CGMP, Pharmaceutical industry

THE WOODLANDS, Texas, and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies, today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.

Key Points: 
  • THE WOODLANDS, Texas, and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies, today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.
  • The ADVA X3® is an advanced, fully automated platform for manufacturing cell therapies, streamlining processes and reducing costs.
  • Additionally, the ADVA X3® system supports cell therapies such as NK, TCR, TIL and exosomes from activation to final cell product.
  • "The collaboration with Cellipont Bioservices is a pivotal moment for us," said Dr. Ohad Karnieli, CEO of Adva Biotechnology.

Cellipont Bioservices and Adva Biotechnology Collaborate to Optimize Cell Therapy Manufacturing with the ADVA X3® Platform

Retrieved on: 
Tuesday, May 7, 2024
Learning, Quality control, Exosome, MD, Partnership, Cell, CDMO, TIL, Biotechnology, Patient, Gene, Society, Health, TCR, Annual general meeting, NK, CGMP, Pharmaceutical industry

THE WOODLANDS, Texas and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies, today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.

Key Points: 
  • THE WOODLANDS, Texas and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies, today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.
  • The ADVA X3® is an advanced, fully automated platform for manufacturing cell therapies, streamlining processes and reducing costs.
  • Additionally, the ADVA X3® system supports cell therapies such as NK, TCR, TIL and exosomes from activation to final cell product.
  • "The collaboration with Cellipont Bioservices is a pivotal moment for us," said Dr. Ohad Karnieli, CEO of Adva Biotechnology.

Beckman Coulter and MeMed Extend Partnership Advancing Host Immune Response Diagnostics

Retrieved on: 
Tuesday, May 7, 2024
Ambiguity, BV, Genetically modified bacteria, TRAIL, Risk, Infection, Procalcitonin, Sepsis, CRP, Septic shock, Partnership, Research, NPV, PCT, Patient, Microbiology, Physician, Ministry, Serum, MDW, Beckman Coulter, CBC, Risk assessment, Viral, US FDA, Vaccine

BREA, Calif. and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in clinical diagnostics, and MeMed, a leader in the emerging field of advanced host-response technologies, today announced expansion of their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed BV® assay, a rapid immunoassay test able to distinguish between bacterial and viral infections, and MeMed Key®, a compact immunoassay analyzer cleared to run the MeMed BV assay in the United States and Europe. This new distribution agreement complements the existing joint effort to develop a MeMed BV-based test for Beckman Coulter's family of Access Immunoassay Analyzers.

Key Points: 
  • BREA, Calif. and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in clinical diagnostics, and MeMed, a leader in the emerging field of advanced host-response technologies, today announced expansion of their host immune response diagnostics partnership.
  • Beckman Coulter is now an authorized distributor of the MeMed BV® assay , a rapid immunoassay test able to distinguish between bacterial and viral infections, and MeMed Key® , a compact immunoassay analyzer cleared to run the MeMed BV assay in the United States and Europe.
  • This new distribution agreement complements the existing joint effort to develop a MeMed BV-based test for Beckman Coulter's family of Access Immunoassay Analyzers .
  • "To that end, we are excited to extend our partnership with MeMed by expanding market access to the MeMed Key and BV assay.

NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility

Retrieved on: 
Thursday, April 25, 2024
NRX, DTC, OTCQB, Exosome, Depository Trust Company, Environment, Tetraplegia, TSX Venture Exchange, Security (finance)

The OTCQB listing enhances visibility and facilitates trading by US institutional and retail investors.

Key Points: 
  • The OTCQB listing enhances visibility and facilitates trading by US institutional and retail investors.
  • As the sole public company developing therapies for spinal cord injury treatment with exosomes, NurExone is proud to broaden its financial market access.
  • The OTCQB, a renowned U.S. trading platform, is a pivotal gateway to US trading, fostering an environment conducive to informed investment decisions.
  • The Company is delighted to announce that it has also received Depository Trust Company ("DTC") eligibility for its shares on the OTCQB.

NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine

Retrieved on: 
Friday, April 19, 2024
NRX, Potential, Patient, Tetraplegia, Therapy, Medical device

Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics and Capricor Therapeutics, as well as senior-level executives in the field.

Key Points: 
  • Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics and Capricor Therapeutics, as well as senior-level executives in the field.
  • As a pioneer and leader in this field, Dr. Shaltiel is well-positioned to provide perspective on exploiting advances in exosomes for drug delivery.
  • NurExone is developing a first exosome-loaded nanodrug, ExoPTEN, for patients who suffer acute Spinal Cord Injuries.
  • To learn more about the summit and to register, please visit the Confere n ce We b site .

INSIGHTEC ANNOUNCES EXABLATE PRIME AVAILABILITY IN EUROPE -THE NEXT GENERATION OF MR-GUIDED FOCUSED ULTRASOUND

Retrieved on: 
Tuesday, April 16, 2024
Sale, Parkinson's disease, SDR, Essential tremor, Safety, Intuition, Research, 3D, Acquisition, Neurosurgery, Physician, DSM-IV codes, AC, Health, Feedback, Temperature, Algorithm, CE

HAIFA, Israel and MUNICH, April 16, 2024 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced the CE approval and European launch of Exablate Prime, a significant enhancement to the Exablate Neuro platform. Based on customer input and feedback, Exablate Prime is the culmination of over 10 years of significant research and development designed to increase precision, efficiency, and experience of the surgeon – and the patient.

Key Points: 
  • Like its predecessor, Exablate Prime enables incisionless neurosurgery as an outpatient procedure to provide relief to people living with movement disorders, such as essential tremor and Parkinson's disease.
  • "Our unwavering commitment to enhancing patient care through innovative technology led us to develop Exablate Prime," said Maurice R. Ferre, M.D.
  • "Although Exablate Neuro has revolutionized the field of neurosurgery, Exablate Prime takes it to entirely new levels, pushing the boundaries of what is possible.
  • "With the growing number of European countries supporting focused ultrasound as viable treatment option for essential tremor, Exablate Prime is truly exciting," commented Giuseppe Carbone, vice president of Insightec Europe.

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

Retrieved on: 
Monday, April 8, 2024
Cell, Environment, Human body, Patient, DSM-IV codes, Patent, PLUR

Pluri’s proprietary 3D cell expansion technology mimics the natural lymph node like environment that immune cells have within the human body.

Key Points: 
  • Pluri’s proprietary 3D cell expansion technology mimics the natural lymph node like environment that immune cells have within the human body.
  • The tightly controlled and fully automated bioreactor system provides cells with the conditions they need in order to expand, enabling efficient expansion of immune cells at scale and quality.
  • Pluri's patented technology marks an important milestone in the field of allogeneic cell therapy, positioning the Company at the forefront of innovation.
  • “Pluri’s patented technology represents a significant leap forward in the field of immune cell expansion, addressing the growing global demand for advanced cell-based therapies.

NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, April 2, 2024
ODD, Research, Growth, Drug discovery, Exercise, NRX, CFO, RNA, Laboratory, Contract research organization, Regenerative medicine, Investigational New Drug, Safety, Spinal cord injury, Intellectual property, Plasma protein binding, Small RNA, FDA, Food, Cryptocurrency

TORONTO and HAIFA, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, today provided a business update and reported financial results for the fourth quarter and financial year ended December 31, 2023.

Key Points: 
  • TORONTO and HAIFA, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, today provided a business update and reported financial results for the fourth quarter and financial year ended December 31, 2023.
  • For the fourth quarter of 2023, expenses were US$0.31 million, compared to US$0.39 million in the previous year.
  • For the fourth quarter of 2023, expenses were US$0.40 million, compared to US$0.46 million in the previous year.
  • For the fourth quarter of 2023, expenses were US$0.02 million, compared to US$0.17 million in the previous year.

Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Plural, Cell, Science, Coffee, Research, Elective surgery, 3D, OA, Carbon, MIW, Osteoarthritis, Education minister, Facial muscles, PLUR

Pluri’s patented coffee cell technology uses the Company’s breakthrough 3D cell expansion technology for mass-scale coffee plant cell cultivation.

Key Points: 
  • Pluri’s patented coffee cell technology uses the Company’s breakthrough 3D cell expansion technology for mass-scale coffee plant cell cultivation.
  • The Company is leveraging two decades of experience and know-how in cell manufacturing to drive the future of coffee science.
  • Pluri’s Chief Executive Officer & President Yaky Yanay will participate in a panel of discussions and Chief Business Development Officer of Pharma Efrat Kaduri will attend the event.
  • It demonstrated increased muscle strength in two clinical studies and is believed to induce systemic anti-inflammatory effect and to reduce post-operative oxidative stress.